75 YAŞ VE ÜZERİ LOKAL İLERİ VE METASTATİK KÜÇÜK HÜCRELİ DIŞI AKCİĞER KANSERİNDE PRİMER VE PALYATİF TEDAVİ OLARAK RADYOTERAPİ UYGULAMASI: 45 VAKANIN DEĞERLENDİRİLMESİ VE LİTERATÜR İNCELEMESİ

Abstract

Amaç: Lokal ileri veya metastatik KHDAK tanılı hastalarda prognostik faktörler ve tedavi sonuçlarının değerlendirilmesi Hastalar ve Yöntem: Yetmiş beş yaş ve üzeri toplam 45 KHDAK tanılı hasta değerlendirildi. Medyan yaş 78 idi (75-93). Otuz dört hasta Evre IIIB (75%), 11 hasta (25%) ise Evre IV olarak evrelendirildi. Evre IIIB tanılı hastaların 14 tanesine (41%) küratif Radyoterapi (RT), 18 hastaya (52%) palyatif RT uygulanırken, 2 hasta (5%) sadece kemoterapi (KT) aldı.

Keywords

• Yaşlı, Akciğer kanseri, Prognostik faktörler, Radyoterapi, Kemoterapi

References

1. Lonardi F, Coeli M, Pavanato G, Adami F, Gioga G,
2. Campostrini F. Radiotherapy for non-small cell lung
3. cancer in patients aged 75 and over, safety, effectiveness
4. and possible impact on survival. Lung Cancer 2000; 28:
5. -50.
6. Tombolini V, Bonanni A, Donato V, et al. Radiotherapy
7. alone in elderly patients with medically inoperable stage
8. IIIA and IIIB non-small cell lung cancer. Anticancer Res

9. ; 20,:4829-4833.
10. Rengan R, Rosenzweig, KE, Venkatraman E, et al.
11. Improved local control with higher doses of radiation in
12. large-volume stage III non-small-cell lung cancer. Int J
13. Radiat Oncol Biol Phys 2004;60:741-747.
14. Finkelstein DM, Ettinger DS, Ruckdeschel JC. Longterm
15. survivors in metastatic non-small cell lung cancer:
16. an Eastern Cooperative Oncology Group Study. J Clin
17. Oncol 1986;4:702–709.
18. Albain KS, Crowley JJ, LeBlanc M, Livingston RB.
19. Survival determinants in extensive-stage non-small cell
20. lung cancer: the Southwest Oncology Group experience.
21. J Clin Oncol 1991; 9: 1618–1626.
22. Borges, M., Sculier, JP., Paesmans, M., et al. Prognostic
23. factors for response to chemotherapy containing
24. platinum derivatives in patients with unresectable nonsmall
25. cell lung cancer (NSCLC). Lung Cancer 1996;16:
26. –33.
27. Stanley, KE. Prognostic factors for survival in patients
28. with inoperable lung cancer. J Natl Cancer Inst
29. ;65:25–32.
30. Hillner BE, McDonald MK, Desch CE, Smith TJ,
31. Penberthy L, Retchin SM. A comparison of patterns of
32. care of nonsmall cell lung carcinoma patients in a
33. younger and Medigap commercially insured cohort.
34. Cancer 1998;83: 1930–1937.
35. Smith TJ, Penberthy L, Desch CE, et al. Differences in
36. initial treatment patterns and outcomes of lung cancer in
37. the elderly. Lung Cancer 1995;13:235–252.
38. Jeremic B, Shibamoto Y. Pre-treatment prognostic
39. factors in patients with stage III non-small cell lung
40. cancer treated with hyperfractionated radiation therapy
41. with or without concurrent chemotherapy. Lung Cancer
42. ; 13: 21–30.
43. Langer C, Hsu C, Curran D, et al. Do elderly patients
44. with locally advanced non-small cell lung cancer benefit
45. from combined modality therapy? A secondary analysis
46. of RTOG 94-10. Int J Radiat Oncol Biol Phys 2001; 51:
47. –21.
48. Gauden SJ, Tripcony L. The curative treatment by
49. radiation therapy alone of Stage I non- small cell lung
50. cancer in a geriatric population. Lung Cancer 2001; 32:
51. –79.
52. Sause W, Kolesar P, Taylor SI, et al. Final results of
53. phase III trial in regionally advanced unresectable nonsmall
54. cell lung cancer: Radiation Therapy Oncology
55. Group, Eastern Cooperative Oncology Group, and
56. Southwest Oncology Group. Chest 2000; 117: 358–364.
57. Newman AB, Yanez D, Harris T, et al. Weight change
58. in old age and its association with mortality. J Am
59. Geriatr Soc 2001; 49: 1309–1318.
60. Movsas B, Scott C, Sause W, et al. The benefit of
61. treatment intensification is age and histology-dependent
62. in patients with locally advanced non-small cell lung
63. cancer (NSCLC): a quality-adjusted survival analysis of
64. radiation therapy oncology group (RTOG)
65. chemoradiation studies. Int J Radiat Oncol Biol Phys
66. ; 45: 1143–1149.
67. Numico G, Russi E, Merlano M. Best supportive care in
68. non-small cell lung cancer: Is there a role for
69. radiotherapy and chemotherapy? Lung Cancer 2001; 32:
70. –226.
71. Chemotherapy in non-small cell lung cancer: a metaanalysis
72. using updated data on individual patients from
73. randomized clinical trials. Non-small Cell Lung
74. Cancer Collaborative Group. BMJ 1995; 311: 899–909.
75. Earle CC, Tsai JS, Gelber RD, et al. Effectiveness of
76. chemotherapy for advanced lung cancer in the elderly:
77. instrumental variable and propensity analysis. J Clin
78. Oncol 2001; 19: 1064–1070.
79. Effects of vinorelbine on quality of life and survival of
80. elderly patients with advanced non-small cell lung
81. cancer. The Elderly Lung Cancer Vinorelbine Italian
82. Study Group. J Natl Cancer Inst 1999; 91: 66–72.
83. Gridelli C, Perrone F, Gallo C, et al. Chemotherapy for
84. elderly patients with advanced non-small cell lung
85. cancer: the Multicenter Italian Lung Cancer in the
86. Elderly Study (MILES) phase III randomized trial. J
87. Natl Cancer Inst 2003, 95: 362–372.
88. Frasci G, Lorusso V, Panza N, et al. Gemcitabine plus
89. vinorelbine versus vinorelbine alone in elderly patients
90. with advanced non-small cell lung cancer. J Clin Oncol
91. ; 18: 2529–2536.
92. Langer CJ, Manola J, Bernardo P, et al. Cisplatin-based
93. therapy for elderly patients with advanced non-small cell
94. lung cancer: implications of Eastern Cooperative
95. Oncology Group 5592, a randomized trial. J Natl Cancer
96. Inst 2002; 94: 173–181.
97. Kelly K, Giarritta S, Akerley W, et al. Should older
98. patients (Pts) receive combination chemotherapy for
99. advanced stage non-small cell lung cancer (NSCLC)?
100. An analysis of Southwest Oncology Trials 9509 and
101. Proc Am Soc Clin Oncol 2001; 20: 329a.
102. Hensing TA, Socinski MA, Schell MJ, et al. Age does
103. not alter toxicity or survival for patients (pts) with stage
104. IIIB/IV non-small cell lung cancer (NSCLC) treated
105. with carboplatin (C) and paclitaxel (P). Proc Am Soc
106. Clin Oncol 2001; 20: 346a.
107. Lilenbaum RC, Herndon J, List M, et al. Single-agent
108. (SA) versus combination chemotherapy (CC) in
109. advanced non-small cell lung cancer (NSCLC): a
110. CALGB randomized trial of efficacy, quality of life
111. (QOL), and cost-effectiveness. Proc Am Soc Clin Oncol
112. ; 21: 1a.
113. -
114. Marmara Medical Journal 2008;21(1);011-020
115. Görkem Aksu, et al.
116. Radiotherapy as the primary and palliative treatment for patients aged 75 or over with locally advanced and metastatic
117. Non-Small Cell Lung Cancer: Analysis of 45 cases with a review of the literature
118. Kris MG, Natale RB, Herbst RS, et al. A phase II trial of
119. ZD1839 (‘Iressa’) in advanced non-small cell lung
120. cancer (NSCLC) patients who had failed platinum- and
121. docetaxel-based regimens (IDEAL 2). Proc Am Soc
122. Clin Oncol 2002; 21: 292a
123. Fukuoka M, Yano S, Giaccone G, et al. Multiinstitutional
124. randomized phase II trial of gefitinib for
125. previously treated patients with advanced non-small cell
126. lung cancer. J Clin Oncol 2003; 21: 2237–2246.